Role of Visfatin as a Marker for Depression in Elderly Patients
DOI:
https://doi.org/10.51985/JBUMDC2019109Keywords:
Geriatric depression, old age institutes, lipid profile, visfatinAbstract
Objective: To identify a new marker for depression amongst the elderly residing in old age institutes (OAI) of Karachi.
Study Design and Setting: This was a case control study which was carried out by visiting different private old age
institutions in the city of Karachi, Pakistan from 2017- 2018.
Methodology: A total of 164 people aged 60 years or more were enrolled via convenient sampling. Basic anthropometric
variables were measured, lipid profile was estimated as well as serum Visfatin was estimated via ELISA and was also
estimated.
Results: The BMI, serum triglyceride and visfatin in depressed subjects were significant with p values < 0.001 **, < 0.004*
and < 0.001* respectively. Systolic blood pressure was highly significant in depressed subjects when compared with control
cases p value < 0.000**.The diastolic blood pressure was significant p value < 0.001* as well. Visfatin was found to be
negatively correlated with triglycerides, BMI and LDL and it was weakly correlated with depression.
Conclusion: The levels of visfatin were found raised in the depressed individuals but they were statistically not significant.
It is suggested that more studies on visfatin can be done to find its association in the identification of depressive symptoms
in patients suffering from depression
References
Patel V, Chisholm D, Parikh R, Charlson F, Degenhardt L, Dua T, Ferrari A, Hyman S, Laxminarayan R, Levin C, Lund
C. Republished: Addressing the burden of mental, neurological, and substance use disorders: key messages from Disease Control Priorities. Indian Journal of Social Psychiatry. 2016;32(3).
Liu Q, He H, Yang J, Feng X, Zhao F, Lyu J. Changes in the global burden of depression from 1990 to 2017: Findings from the Global Burden of Disease study. Journal of psychiatric research. 2019 Aug 10.
Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd- Allah F, Abdulkader RS, Abdulle AM, Abebo TA, Abera SF, Aboyans V. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet. 2017 ; 390(10100):1211-59.
Ogbo FA, Mathsyaraja S, Koti RK, Perz J, Page A. The burden of depressive disorders in South Asia, 1990–2016: findings from the global burden of disease study. BMC psychiatry. 2018;18(1):333.
Kumar CS, George S, Augustine A. Treatment of late-life depression. Journal of Geriatric Care and Research. 2020;7(1).
Stone LE, Granier KL, Segal DL. Geriatric Depression Scale. DOI: 10.1007/978-3-319-69892-2_736-1.
The Express Tribune. Growing old: Ageing population brings novel challenges. [Online] 2012.[Cited 2020 February 21].
Cassum LA, Cash K, Qidwai W, Vertejee S. Exploring the experiences of the older adults who are brought to live in shelter homes in Karachi, Pakistan: a qualitative study.
Esmaeilzadeh S, Oz F. Effect of psychosocial care model applied in an “elderly day care center” on loneliness, depression, quality of life, and elderly attitude. Nigerian Journal of Clinical Practice. 2020;23(2):189.
Sonoli S, Shivprasad S, Prasad C, Patil A, Desai P, Somannavar
M. Visfatin–a review. Eur Rev Med Pharmacol Sci. 2011; 15:9-14.
Mohammadi M, Mianabadi F, Mehrad-Majd H. Circulating visfatin levels and cancers risk: A systematic review and meta- analysis. Journal of cellular physiology. 2019;234(4):5011- 22.
Larrad MT, Anchuelo AC, Pérez CF, Barba MP, Redondo YL, Ríos MS, Segovia Insulin Resistance Study Group. Obesity and Cardiovascular Risk: Variations in Visfatin Gene Can Modify the Obesity Associated Cardiovascular Risk. Results from the Segovia Population Based-Study. Spain. PloS ONE. 2016; 11(5):e0153976.
Hedayati M, Hakami M, Hedayati M. Association between Serum Levels of Visfatin and Binge Eating Disorders in Overweight Women.
Ambrósio G, Kaufmann FN, Manosso L, Platt N, Ghisleni G, Rodrigues AL, Rieger DK, Kaster MP. Depression and peripheral inflammatory profile of patients with obesity. Psychoneuroendocrinology. 2018;91:132-41.
Palazidou E. The neurobiology of depression. British medical bulletin. 2012;101(1):127-45.
Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BWet al(2010).Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies.Arch Gen Psychiatry 67:220–229
Capuron L, Lasselin J, Castanon N. Role of adiposity-driven inflammation in depressive morbidity. Neuropsycho- pharmacology. 2017;42(1):115.
Khuwaja AK, Lalani S, Dhanani R, Azam IS, Rafique G, White F. Anxiety and depression among outpatients with type 2 diabetes: A multi-centre study of prevalence and associated factors. Diabetology & metabolic syndrome. 2010;2(1):72.
Scalco AZ, Scalco MZ, Azul JB, Lotufo Neto F. Hypertension and depression, Clinics. 2005; 60(3): 241-50.
Krousel-Wood MA, Frohlich ED. Hypertension and depression: coexisting barriers to medication adherence. The Journal of Clinical Hypertension. 2010;12(7):481-6.
Bogner HR, de Vries HF. Integration of depression and hypertension treatment: a pilot, randomized controlled trial. The Annals of Family Medicine. 2008;6(4):295-301.
Yu PL, Wang C, Li W, Zhang FX. Visfatin Level and The Risk of Hypertension and Cerebrovascular Accident: A Systematic Review and Meta-Analysis. Hormone and Metabolic Research. 2019;51(04):220-9.
Liu Q, Cai H, Yang LH, Xiang YB, Yang G, Li H, Gao YT, Zheng W, Susser E, Shu XO. Depressive symptoms and their association with social determinants and chronic diseases in middle-aged and elderly Chinese people. Scientific reports. 2018;8(1):3841.
Zhang L, Liu K, Li H, Li D, Chen Z, Zhang LL, Guo LL. Relationship between body mass index and depressive symptoms: the “fat and jolly” hypothesis for the middle-aged and elderly in China, BMC public health. 2016;16(1):1201.
Kim J, Noh JW, Park J, Kwon YD. Body mass index and depressive symptoms in older adults: a cross-lagged panel analysis. PLoS One. 2014;9(12):e114891.
Dearborn PJ, Robbins MA, Elias MF. Challenging the “jolly fat” hypothesis among older adults: High body mass index predicts increases in depressive symptoms over a 5-year period. Journal of health psychology. 2018; 23(1):48-58.
Owczarek AJ, Olszanecka-Glinianowicz M, Koce³ak P, Bo¿entowicz-Wikarek M, Brzozowska A, Mossakowska M, Puzianowska-KuŸnicka M, Grodzicki T, Wiêcek A, Chudek
J. The relationship between circulating visfatin/nicotinamide phosphoribosyltransferase, obesity, inflammation and lipids profile in elderly population, determined by structural equation modeling. Scandinavian journal of clinical and laboratory investigation. 2016;76(8):632-40.
Zhang LQ, Van Haandel L, Xiong M, Huang P, Heruth DP, Bi C, Gaedigk R, Jiang X, Li DY, Wyckoff G, Grigoryev DN. Metabolic and molecular insights into an essential role of nicotinamide phosphoribosyltransferase. Cell death & disease. 2017; 8(3):e2705.
Romacho T, Villalobos LA, Cercas E, Carraro R, Sánchez- Ferrer CF, Peiró C. Visfatin as a novel mediator released by inflamed human endothelial cells. PloS one. 2013;8(10): e78283.
Gunes F, Akbal E, Cakir E, Akyurek O, Altunbas M, Ozbek
M. Visfatin may be a novel marker for identifying stages of essential hypertension in advanced age patients. Internal Medicine. 2012;51(6):553-7.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Sabeen H. Qazi, Shaista Emad, Rubina Ghani
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of Bahria University Medical & Dental College is an open access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0 
